R Squared’s Karyopharm Therapeutics KPTI Stock Holding History

R Squared’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,978	Closed	-$20.1K	–	923
2024 Q4	$20.1K	Buy	+1,978	New	+$23.9K	0.02%	875

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

R Squared's KPTI Position: Q1 2025 in Review

R Squared sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 1,978 shares — an estimated $20.1K sold.

R Squared first reported a position in KPTI in Q4 2024 and held it in 1 quarter. The position peaked at $20.1K in Q4 2024. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

R Squared reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 1,978 Karyopharm Therapeutics shares in Q1 2025, an estimated $20.1K.
R Squared first reported a position in Karyopharm Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Karyopharm Therapeutics position peaked at $20.1K in Q4 2024.
49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.